MB-CART20.1 Melanoma

Inclusion Criteria: Male or female patients with * Histologically confirmed unresectable stage III or stage IV melanoma * Willingness to provide a tumor biopsy between the screening visit and prior to administration of the IMP and eight weeks after treatment * Progressive disease despite treatment with indicated standard therapies. Time window for decision about progressive disease is to be made depending on the treatment regimen chosen. * Measurable lesions according to RECIST1.1 * ECOG (Eastern cooperative oncology group) performance status of 0-2 * Negative serological hepatitis B (HBV) test defined as negative tests for HBsAg and HBcAb, unless serology is positive due to recent IVIG therapy, HBcAb positivity will be allowed if HbsAb is present, negative testing of HCVAb, negative human immunodeficiency virus (HIV) 1/2 test within 6 weeks prior to enrollment. * Estimated life expectancy of more than 6 months * At least 18 years of age * WBC ≥ 2500/µL * ANC ≥ 1000/µL * Platelets ≥ 75 x 103/µL * Hemoglobin ≥ 9 g/dL * AST ≤ 3 x upper limit of normal (ULN) for patients without liver metastasis * AST \< 5 x ULN for patients with liver metastasis * Total Bilirubin ≤ 2 x ULN * patients with Gilbert's Syndrome increase of indirect bilirubin \< 6mg/dL * No childbearing potential (i.e. postmenopausal, absence of menstrual bleeding for at least 1 year, hysterectomy, bilateral ovariectomy or tubal section/ligation) or negative pregnancy test at screening and before chemotherapy in w…